How GlaxoSmithKline Stock Has Performed in September



About GlaxoSmithKline

GlaxoSmithKline (GSK), a global pharmaceutical company, is focused on creating a sustainable growth model through expanding its business beyond pharmaceuticals. GlaxoSmithKline reports its financial statements in sterling pounds. GlaxoSmithKline ADR fell marginally by ~0.1% as compared to its previous close to the closing price of $40.51 on September 27.

The above chart shows the changes in analysts’ recommendations for GlaxoSmithKline since January 2018.

Article continues below advertisement

GlaxoSmithKline’s performance

GlaxoSmithKline ADR’s price has been nearly flat in September 2018 to date, while the stock price has decreased by nearly 2.1% over the last one month. GlaxoSmithKline also reported a 0.3% increase in its price over the last 12 months and a 14.2% increase in its price in 2018 year-to-date.

Analyst estimates suggest the stock could rise ~6.3% over the next 12 months. Wall Street analysts have given the stock a 12-month target price of $43.06 per share as compared to its price of $40.51 per share on September 27, 2018.

Analyst recommendations

As of September 28, 2018, there are five analysts tracking GlaxoSmithKline ADR listed on the NYSE. One analyst recommends a “strong buy,” while four analysts recommend a “hold.” The consensus rating for GlaxoSmithKline stands at 2.60, which represents a hold for investors.

GlaxoSmithKline stock listed on the London Stock Exchange has risen ~3.8% in the last 12 months and 16.6% in 2018 year-to-date. 25 analysts are tracking GlaxoSmithKline stock listed on the London Stock Exchange. Three of these analysts recommend a “strong buy,” nine analysts recommend a “buy,” 12 analysts recommend a “hold,” and one analyst recommends a “sell.” The consensus rating for GlaxoSmithKline stock stands at 2.44, representing a “buy” for value investors.

The Invesco Zacks Multi-Asset Income ETF (CVY) holds 0.7% of its portfolio in GlaxoSmithKline (GSK), 1.0% in Gilead Sciences (GILD), 1.0% in Cardinal Health (CAH), and 1.1% in Amgen (AMGN).


More From Market Realist